fate therapeutics buyout fate therapeutics buyout

How were Fate Therapeutics' earnings last quarter? Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high. This suggests a possible upside of 304.1% from the stock's current price. Topics covered: Drug commercialization, pharma salesforces, generic and biosimilar competition, drug advertising and much more. Published: Apr 03, 2020 As analyst firm Jefferies noted in March, Precision,AllogeneTherapeutics and CRISPRTherapeutics, which each use different off-the-shelf approaches, could all produce notable human data this year. The shares were sold at an average price of $5.24, for a total transaction of $240,552.68. About Biotech Acquisition Company. In other Fate Therapeutics news, CEO J Scott Wolchko sold 45,907 shares of the firms stock in a transaction on Tuesday, January 10th. And the recent stock price growth means that some of the positives are already priced in at the current price of $114. By Alex Keown. The company has a market cap of $583.99 million, a price-to-earnings ratio of -1.97 and a beta of 1.46. Out of 352 instances in the last eight years that Fate Therapeutics stock saw a five-day rise of 9% or more, 178 of them resulted in FATE stock rising over the subsequent one month period (twenty-one trading days). A month has gone by since the last earnings report for Fate Therapeutics (FATE). My No. Now that the stock has seen a strong run up over the recent months, and given that the company is far away from any significant revenue growth, we believe that it is vulnerable to downside risk. The official website for the company is www.fatetherapeutics.com. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. The company employs 449 workers across the globe. Janssen agreed to pay Fate $50 million upfront, while another J&J entity, Johnson & Johnson Innovation-JJDC, will purchase newly-issued shares of Fate's common stock at a price per share of . Since then, FATE stock has decreased by 39.4% and is now trading at $6.11. Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. Research & Development expenses surged to $44.8 million from $29.3 million in the year-ago quarter. Fate Therapeutics (NASDAQ:FATE - Get Rating) had its price target upped by equities research analysts at Citigroup from $9.00 to $10.00 in a report issued on Thursday, The Fly reports. It appears so. Fate turns cells from donors into induced pluripotent stem cells, which in turn can be re-engineered into a variety of different cells. Fate is in the mix, too, though it acknowledged COVID-19 could impact its plans. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! Lazard Asset Management LLC owned approximately 0.17% of Fate Therapeutics worth $3,616,000 at the end of the most recent quarter. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Inventors: Bahram Valamehr, Peter Flynn, Ramzey Abujarour, Megan Robinson Methods and compositions for inducing hematopoietic cell differentiation Patent number: 11162076 Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. Opinions expressed by Forbes Contributors are their own. New U.S. cancer drug prices rise 53% in five years - report. But how would these numbers change if you are interested in holding FATE stock for a shorter or a longer time period? Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high. A class action has already been filed. Learn more The stock was purchased at an average cost of $5.67 per share, for a total transaction of $499,232.16. 1 dividend stock for a LIFETIME of income. While FATE stock may be overvalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Reserve Your Spot With These Hotels The Analysts Support, Cruise Line Stocks Still Have Some Choppy Waters to Navigate, Four Vegan Food Stocks Performing Beyond the Norm, MarketBeat.com's FREE daily email newsletter, Kroger Shares Gap Up on Better-Than-Expected Earnings. The decline is driven in part by the broader sell-off in high growth stocks. Sign in to your free account to enjoy all that MarketBeat has to offer. This company's $6.7 billion market cap at the moment assumes a great deal of success down the road. In the last 90 days, insiders have sold 75,708 shares of company stock valued at $396,710. The average twelve-month price prediction for Fate Therapeutics is $24.69 with a high price target of $90.00 and a low price target of $7.00. If response rates for its treatments fall, as is usually the case in cancer trials, this stock . The outperformance of FATE can be attributed to positive findings from early clinical trials of FT500 and FT516 treatments. FT819. First-generation autologous CAR-T therapies involve genetically edited immune cells taken directly from patients in a lengthy, logistically challenging and costly procedure. One share of FATE stock can currently be purchased for approximately $6.11. On corrections down, there will be some support from the lines at $63.99 and $66.95. Fate Therapeutics became the first entity to dose a patient with an engineered stem cell-derived cellular medicine in October, began enrolling a higher-dose cohort for a separate drug. Fate Therapeutics has a 52 week low of $4.02 and a 52 week high of $43.12. Fate Therapeutics will receive a $50 million upfront payment and a $50 million equity investment. All rights reserved. It has seen positive findings from early trials for FT500, something that has kept the stock price buzzing of late. Fate Therapeutics Market Cap Make that two consecutive days of riding the momentum from the Juno Therapeutics acquisition. About Fate Therapeutics, Inc. Raymond James & Associates now owns 29,436 shares of the biopharmaceutical companys stock worth $1,141,000 after purchasing an additional 8,790 shares during the period. Posted by MarketBeat News on Mar 2nd, 2023. That said, given the current momentum in FATE stock, and the positive data from clinical trials will likely result in continued growth in FATE stock in the near term. FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (FDBU), a FUJIFILM Corporation subsidiary, today announced the completion of its acquisition of Kalon Biotherapeutics LLC, marking an important new chapter in the emergence of the Texas biosciences industry as a center for world-class development and manufacturing of life-saving biopharmaceuticals and Its pretty powerful to test the trend for yourself for Fate Therapeutics stock by changing the inputs in the charts above. If you wish to serve as lead plaintiff, you . Per deal terms, J&J will buy $50 million Fate shares at $31 apiece, a roughly 47% premium to Fate's $21.07 closing price on Thursday. Five Day: FATE 16%, vs. S&P500 4%; Outperformed market, Ten Day: FATE 13%, vs. S&P500 1.8%; Outperformed market. You may opt-out by. In announcing the J&J deal, Fate also warned of coronavirus-related "delays or disruptions in patient enrollment and site initiation" that will affect the timing of its clinical trials. Fate has been focused on the oncology and immunology pipeline for multiple cancer types including myeloid leukemia, B-cell lymphoma, and multiple myeloma among others. The company's quarterly revenue was up 159.9% on a year-over-year basis. Natixis bought a new stake in Fate Therapeutics in the 4th quarter worth $29,000. March 1, 2023|markets.businessinsider.com, February 27, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com, February 13, 2023|markets.businessinsider.com. I, Fate Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($0.75) Per Share (NASDAQ:FATE), Q1 2023 EPS Estimates for Fate Therapeutics, Inc. (NASDAQ:FATE) Reduced by Analyst, Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript, Fate Therapeutics Full Year 2022 Earnings: Beats Expectations. Try the Trefis machine learning engine above to see for yourself how Fate Therapeutics stock is likely to behave after any specific gain or loss over a period. But how would these numbers change if you are interested in holding FATE stock for a shorter or a longer time period? The fund owned 153,051 shares of the biopharmaceutical company's stock after purchasing an additional 3,038 shares during the period. Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Fate Therapeutics had a negative trailing twelve-month return on equity of 50.86% and a negative net margin of 292.55%. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Former Qualcomm CEO Steven Mollenkopf, who retired in June 2021, pulled in total compensation of $69 million last year, which ranked highest among CEOs of the region's 100 publicly traded companies. Transforming the lives of patients with cancer and immune disorders. U.S. regulators rejected Elon Musks bid to test brain chips in humans, Cell and Gene Therapy Manufacturing: Current and Future States, Proven Tips for Converting Sites to Single IRB, GSKs RSV vaccine wins FDA panel backing, matching Pfizer, FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs. The company is currently working on multiple programs, including FT516 for the treatment of acute myeloid leukemia and B-cell lymphoma, FT596 to treat B-cell lymphoma, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. What happened When Celgene announced it was acquiring Juno. The companys approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. [Updated: 1/20/2021] Is FATE Stock Overbought? Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. Fate Therapeutics (NASDAQ:FATE) Price Target Lowered to $7.00 at Piper Sandler, Fate Therapeutics (NASDAQ:FATE) Receives "Buy" Rating from EF Hutton Acquisition Co. Among them: Pfizer's wide-ranging deal with Allogene Therapeutics in 2018 as well as Bayer's buyout of BlueRock Therapeutics and investment in Century Therapeutics last year. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. View institutional ownership trends. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks - although FATE stock appears to be an exception to this general observation. UBS Group AG Reduces Stock Holdings in Builders FirstSource, Inc. Boothbay Fund Management LLC Has $299,000 Stock Holdings in GMS Inc. What is Fate Therapeutics' stock price forecast for 2023? Also, CEO J Scott Wolchko sold 45,907 shares of the stock in a transaction dated Tuesday, January 10th. The firm owned 161,373 shares of the biopharmaceutical companys stock after selling 59,987 shares during the quarter. Fate is all of that. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. [3] 2000 was the year that saw the most new Israeli listings on the exchange - 33 companies. What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading sessions. Truist Financial reiterated a hold rating and issued a $7.00 target price (down from $46.00) on shares of Fate Therapeutics in a research note on Friday, January 6th. 22 Wall Street research analysts have issued twelve-month price objectives for Fate Therapeutics' stock. See what's happening in the market right now with MarketBeat's real-time news feed. Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Tuesday, February, 28th. Topics covered: startup launches, funding, IPOs and much more. [] The 9% rise can primarily be attributed to the announcement of positive interim data from a phase one study for patients with relapsed or refractory B-cell lymphoma. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Lazard Asset Management LLC lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Rating) by 27.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Shares climbed about 20%, to around $25 apiece, in pre-market trading Friday. Horizon Therapeutics becomes target of acquisition by pharma giants. FATE stock has rallied from $22 to $114, significantly outperforming the S&P which moved 70% over the same period, with the resumption of economic activities as lockdowns are gradually lifted and vaccines are being approved in multiple countries. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers . Market Volatility To Continue Its The Economy (Stupid)! More importantly, there is 60% probability of a positive return over the next twenty-one trading days and a 53% probability of a positive excess return after a -5% change over five trading days, based on historical data. While we believe that FATE stock is richly valued, the market potential is huge, especially in multi-billion dollar - oncology treatments. Fate will advance the different candidates through preclinical studies to the point of the filing of an Investigational New Drug Application with the U.S. Food and Drug Administration. Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $599.76 million and generates $96.30 million in revenue each year. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"). Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? Fates revenue did grow a solid 160% from $4.1 million in 2017 to $10.7 million in 2019. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications. Analysts like Fate Therapeutics less than other Medical companies. What is a Good Dividend Yield? You can test the answer and many other combinations on the Trefis Machine Learning Engine to test Fate Therapeutics stock chances of a rise after a fall. For example, youll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck.See allTrefis Featured AnalysesandDownloadTrefis Datahere, This is a BETA experience. 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. Powered by Madgex Job Board Software. FATE stock fares better after Case 1, with an average return of 6% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 3.8% for Case 2. Fate Therapeutics delivered mixed results for its lymphoma treatments, which caused Fate stock to crumble on Friday.. X. According to analysts' consensus price target of $24.69, Fate Therapeutics has a forecasted upside of 305.4% from its current price of $6.09. You can test the chance of recovery over different time intervals of a quarter, month, or even just one day! Using the recent trend (20% fall in a week) and seven years of historical stock data, the Trefis AI engine finds that the stock will likely move 15.1% over the next one month (twenty-one trading days), outperforming the broader indices. Large investors have recently added to or reduced their stakes in the company. Get short term trading ideas from the MarketBeat Idea Engine. Fate Therapeutics' stock is owned by a variety of institutional and retail investors. It has seen positive findings from early trials for FT500, preventing disease progression for 11 out of 15 patients, something that has kept the stock price buzzing of late. Fate Therapeutics has a P/B Ratio of 0.86. According to the Trefis Machine Learning Engine, which identifies trends in a companys stock price using historical stock data, returns for FATE stock average around 6% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). Fate is working toward a class of treatment that is based on NK cells. Eight of 11 lymphoma patients who received one Fate NK cell therapy, FT516, have shown evidence of a response, as have 10 of 14 given . While we believe that FATE stock is richly valued, the market potential is huge, especially in multi-billion dollar - oncology treatments. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. 333-228513) that was previously filed by Fate . FT819 is a first-of-kind, allogeneic, off-the-shelf CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line precisely engineered to insert a novel 1XX anti-CD19 chimeric antigen receptor (CAR) under the regulation of the T-cell receptor alpha constant (TRAC) locus for optimized control of anti-tumor activity and to completely delete T-cell receptor (TCR . Fate Therapeutics has raised a total of $1.2B in funding over 16 rounds. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Overall, according to data and Trefis machine learning engines calculations, patience absolutely pays for most stocks! Answer: The average return after a rise is understandably lower than a fall as detailed in the previous question. Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. Fate has been focused on the oncology and immunology pipeline for multiple cancer types including myeloid leukemia, B-cell lymphoma, and multiple myeloma among others. It does make sense given oncology is a high value market and a single drug approval in this space would mean a significant growth in the companys sales from the $20 million currently. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. Glassdoor has salaries, wages, tips, bonuses, and hourly pay based upon employee reports and estimates. It appears so. Fate Therapeutics does not currently pay a dividend. The disclosure for this sale can be found here. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. Notably, though, the stock is likely to beat S&P500 returns by 4% over the next month (twenty-one trading days). Their latest funding was raised on Jan 4, 2021 from a Post-IPO Equity round. See our analysis on Fate Therapeutics Stock Chances of Rise for more details. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. Its pretty powerful to test the trend for yourself for Fate Therapeutics stock by changing the inputs in the charts above. Answer: If you buy and hold Fate Therapeutics stock, the expectation is over time the near term fluctuations will cancel out, and the long-term positive trend will favor you - at least if the company is otherwise strong. These companies have yet to prove off-the-shelf approaches can match, or surpass, what has been seen with CAR-T without triggering serious or potentially deadly immune reactions. Shares of FATE opened at $6.01 on Tuesday. Insiders have sold a total of 75,708 shares of company stock worth $396,710 in the last ninety days. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. MACHINE LEARNING ENGINE try it yourself: IF FATE stock moved by -5% over five trading days, THEN over the next twenty-one trading days, FATE stock moves an average of 6%, which implies an excess return of 4% compared to the S&P500. Fate Therapeutics' stock was trading at $10.09 at the beginning of the year. The stock was sold at an average price of $5.24, for a total transaction of $38,414.44. The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen-binding domains while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Wolchko said in a statement. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. Now, is FATE stock poised to gain further? NDAQ P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. A change of 16% or more over 5 trading days is a 9% likelihood event, which has occurred 114 times out of 1256 in the last 5 years, A change of 13% or more over 10 trading days is a 20% likelihood event, which has occurred 252 times out of 1240 in the last 5 years. [1] [2] As of 2011, some sixty Israeli companies are listed on the Nasdaq. No additional study drug will be given, but subjects can receive other therapies for their cancer while they . MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. [Updated: 1/20/2021] Is FATE Stock Overbought? The stock has a market cap of . More importantly, there is 60% probability of a positive return over the next twenty-one trading days and a 53% probability of a positive excess return after a -5% change over five trading days, based on historical data. Separately, Fate Therapeutics Chief Scientific Officer - Daniel Shoemaker - will be leaving the company in June this year, and this development has likely hurt the stock. At Tuesday's closing price,. Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Purchases New Holdings in Ball Co. (NYSE:BALL), Blueshift Asset Management LLC Sells 21,016 Shares of Dell Technologies Inc. (NYSE:DELL), Cary Street Partners Investment Advisory LLC Has $126,000 Stock Holdings in Yum China Holdings, Inc. (NYSE:YUMC). The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Fate Therapeutics is currently working on multiple programs, including FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors, and the developments around the clinical trials for these treatments has kept its stock buzzing of late. Now that the stock has seen a strong run up over the recent months, and given that the company is far away from any significant revenue growth, we believe that it is vulnerable to downside risk. Do Wall Street analysts like Fate Therapeutics more than its competitors? Giu 11, 2022 | narcissistic withdrawal. Specifically, ARK Genomic Revolution ETF ( NYSEARCA: ARKG) bought 55,163 shares of Fate Therapeutics, and ARK Innovation ETF ( NYSEARCA: ARKK) bought 186,114 shares. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. It has seen positive findings from early trials for FT500, something that has kept the stock price buzzing of late. Will Boston Scientific Stock See Higher Levels? After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has reached its near-term potential. CULVER CITY & EL SEGUNDO, Calif., March 9, 2021 ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger.This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of . Looking at the recent rally, the 9% rise for FATE stock over the last five days compares with a 0.7% growth seen in the broader S&P 500 index. Compare Top Brokerages Here. The 16% rise for FATE stock compares with 4% gains seen in the broader S&P 500 index. Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. It is engaged in the development of programmed cellular immunotherapies for cancer and immune. Fate Therapeutics is funded by 8 investors. Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. UBS Group AG Reduces Stock Holdings in Builders FirstSource, Inc. (NYSE:BLDR), Boothbay Fund Management LLC Has $299,000 Stock Holdings in GMS Inc. (NYSE:GMS), Alphabet Inc. (NASDAQ:GOOG) Shares Bought by Capital Square LLC, Jeereddi Investments LP Increases Position in Alphabet Inc. (NASDAQ:GOOG), Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products (NYSE:SON), Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. (NYSE:GGG), MML Investors Services LLC Buys 3,360 Shares of Wolfspeed, Inc. (NYSE:WOLF), Boothbay Fund Management LLC Takes Position in Loews Co. (NYSE:L), Boothbay Fund Management LLC Sells 9,611 Shares of Portillos Inc. (NASDAQ:PTLO), MML Investors Services LLC Sells 139 Shares of Extra Space Storage Inc. (NYSE:EXR), Lazard Asset Management LLC Has $308,000 Stake in Marqeta, Inc. (NASDAQ:MQ), Lazard Asset Management LLC Has $329,000 Position in The Williams Companies, Inc. (NYSE:WMB), Boothbay Fund Management LLC Invests $267,000 in Synaptics Incorporated (NASDAQ:SYNA), 7,728 Shares in SEI Investments (NASDAQ:SEIC) Acquired by Ergoteles LLC, Lazard Asset Management LLC Trims Stake in iQIYI, Inc. (NASDAQ:IQ), 2,549 Shares in Hess Co. (NYSE:HES) Acquired by Boothbay Fund Management LLC, The Interpublic Group of Companies, Inc. (NYSE:IPG) Shares Sold by Lazard Asset Management LLC, Boothbay Fund Management LLC Acquires 38,651 Shares of Consolidated Communications Holdings, Inc. (NASDAQ:CNSL), Boothbay Fund Management LLC Takes $260,000 Position in Advanced Drainage Systems, Inc. (NYSE:WMS), Boothbay Fund Management LLC Takes $288,000 Position in ShotSpotter, Inc. (NASDAQ:SSTI). Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen's Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m. EST